• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of efficacy supplements received in the quarter (1)

Dictionary: Efficacy Supplements to New Drug Applications (NDAs), Biologics License Applications (BLAs), Post Marketing Application (PMA) Panel Track, Abbreviated New Drug Application (ANDAs) and Biosimilar Biological Product Applications (BBPAs) are submissions that will make a change to an approved marketing application. This change may include a new or expanded indication, new routes of administration, revisions to the dosage or dosing regimen, or improved safety. This measure track’s CBER’s performance in issuing decisions within established timeframes.

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetNumber
Oct 2011N/A0
Nov 2011N/A0
Dec 2011N/A5
Jan 2012N/A0
Feb 2012N/A1
Mar 2012N/A2
Apr 2012N/A0
May 2012N/A2
Jun 2012N/A1
Jul 2012N/A2
Aug 2012N/A1
Sep 2012N/A1

FY 2012 Total: 15

Footnotes

  • (1) Beginning October 2012, this measure will be reported quarterly

Number of overdue efficacy supplements at the end of the quarter (1)

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetNumber
Oct 2011N/A0
Nov 2011N/A0
Dec 2011N/A0
Jan 2012N/A0
Feb 2012N/A0
Mar 2012N/A0
Apr 2012N/A0
May 2012N/A0
Jun 2012N/A0
Jul 2012N/A0
Aug 2012N/A0
Sep 2012N/A0

FY 2012 Total: 0

Footnotes

  • (1) Beginning October 2012, this measure will be reported quarterly.

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.